About: Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus
Creator	Zhang, Yi Lee, Tae-Young Shi, Wei Yang, Jeong-Sun Kim, Dae-Won Wang, Lingshu Woo, Hye-Min Park, Woo-Jung Lee, Joo-Yeon Choi, Jang-Hoon Yun, Mi-Ran Mascola, John Graham, Barney Kim, Joo Kim, Sung Mclellan, Jason Lee Id, Hansaem Lee, So-Young Shim, Sang-Mu Wang, Nanshuang
Source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection and continues to infect humans, thereby contributing to a high mortality rate (34.3% in 2019). In the absence of an available licensed vaccine and antiviral agent, therapeutic human antibodies have been suggested as candidates for treatment. In this study, human monoclonal antibodies were isolated by sorting B cells from patient’s PBMC cells with prefusion stabilized spike (S) probes and a direct immunoglobulin cloning strategy. We identified six receptor-binding domain (RBD)-specific and five S1 (non-RBD)-specific antibodies, among which, only the RBD-specific antibodies showed high neutralizing potency (IC(50) 0.006–1.787 μg/ml) as well as high affinity to RBD. Notably, passive immunization using a highly potent antibody (KNIH90-F1) at a relatively low dose (2 mg/kg) completely protected transgenic mice expressing human DPP4 against MERS-CoV lethal challenge. These results suggested that human monoclonal antibodies isolated by using the rationally designed prefusion MERS-CoV S probe could be considered potential candidates for the development of therapeutic and/or prophylactic antiviral agents for MERS-CoV human infection.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0232757
bibo:pmid	32384116
has license	cc0
sha1sum (hex)	43599a3ac334604e78f519436af7092c19ffafba
schema:url	https://doi.org/10.1371/journal.pone.0232757
resource representing a document's title	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus
has PubMed Central identifier	PMC7209324
has PubMed identifier	32384116
schema:publication	PLoS One
resource representing a document's body	covid:43599a3ac334604e78f519436af7092c19ffafba#body_text
is schema:about of	named entity 'mortality rate' named entity 'severe' named entity 'antiviral agent' named entity 'sorting' named entity 'Middle East respiratory syndrome' named entity 'spike' named entity 'MONOCLONAL ANTIBODIES' named entity 'INFECTION' named entity 'CAUSES' named entity 'HUMAN' named entity 'ANTIBODY' named entity 'SEVERE' covid:arg/43599a3ac334604e78f519436af7092c19ffafba named entity 'specific' named entity 'therapeutic' named entity 'patient' named entity 'human monoclonal antibodies' named entity 'highly' named entity 'Bar Harbor' named entity 'MERS-CoV' named entity 'mononuclear cell infiltration' named entity 'amino acids' named entity 'DPP4' named entity 'high' named entity 'continues' named entity 'candidates' named entity 'candidates' named entity 'potency' named entity 'affinity' named entity 'human' named entity 'immunoglobulin' named entity 'cloning' named entity 'MERS-CoV' named entity 'human monoclonal antibodies' named entity 'vaccine' named entity 'mortality rate' named entity 'antiviral agent' named entity 'lethal' named entity 'RBD' named entity 'pseudovirus' named entity 'variable regions' named entity 'PBS' named entity 'Histopathological' named entity 'MERS-CoV' named entity 'DNase' named entity 'IgG' named entity 'Uppsala' named entity 'Invitrogen' named entity 'viruses' named entity 'light chain' named entity 'antibodies' named entity 'PCR' named entity 'viral genome' named entity 'MERS-CoV' named entity 'postfusion' named entity 'computational modeling' named entity 'animal models' named entity 'Sunnyvale' named entity 'spike protein' named entity 'Korea' named entity 'methanol' named entity 'mAbs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software